Prism biotech in motion: fda approval for panbela therapeutics pediatric cancer drug; shares jump 120%

New york, december 20, 2023 – prism marketview, a leading provider of unbiased market insight and company news, today highlights panbela therapeutics, inc. which has announced that us worldmeds®1 (uswm) has received fda approval of its new drug application (nda) for the use of eflornithine as a maintenance therapy for high-risk neuroblastoma patients.
PBLA Ratings Summary
PBLA Quant Ranking